Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Johannsson, G, Bidlingmaier, M, Biller, B, Boguszewski, M, Casanueva, FF, Chanson, P, Choong, CS, Clayton, PE, Clemmons, D, Dattani, M, Frystyk, J, Ho, KKY, Hoffman, A, Horikawa, R, Juul, A, Kopchick, J, Luo, X, Neggers, S, Netchine, I, Olsson, DS, Radovick, S, Rosenfeld, RG, Ross, RJ, Schilbach, K, Collett-Solberg, PF, Strasburger, CJ, Trainer, PJ, Wickstrom, K, Yuen, KC & Jørgensen, JOL 2018, 'Growth Hormone Research Society perspective on biomarkers of GH action in children and adults' Endocrine Connections, vol. 7, no. 3, pp. R126-R134. https://doi.org/10.1530/EC-18-0047

APA

Johannsson, G., Bidlingmaier, M., Biller, B., Boguszewski, M., Casanueva, F. F., Chanson, P., ... Jørgensen, J. O. L. (2018). Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections, 7(3), R126-R134. https://doi.org/10.1530/EC-18-0047

CBE

Johannsson G, Bidlingmaier M, Biller B, Boguszewski M, Casanueva FF, Chanson P, Choong CS, Clayton PE, Clemmons D, Dattani M, Frystyk J, Ho KKY, Hoffman A, Horikawa R, Juul A, Kopchick J, Luo X, Neggers S, Netchine I, Olsson DS, Radovick S, Rosenfeld RG, Ross RJ, Schilbach K, Collett-Solberg PF, Strasburger CJ, Trainer PJ, Wickstrom K, Yuen KC, Jørgensen JOL. 2018. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections. 7(3):R126-R134. https://doi.org/10.1530/EC-18-0047

MLA

Vancouver

Johannsson G, Bidlingmaier M, Biller B, Boguszewski M, Casanueva FF, Chanson P et al. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections. 2018;7(3):R126-R134. https://doi.org/10.1530/EC-18-0047

Author

Johannsson, Gudmundur ; Bidlingmaier, Martin ; Biller, Beverly ; Boguszewski, Margaret ; Casanueva, Felipe F ; Chanson, Philippe ; Choong, Catherine S ; Clayton, Peter E ; Clemmons, David ; Dattani, Mehul ; Frystyk, Jan ; Ho, Ken K Y ; Hoffman, Andrew ; Horikawa, Reiko ; Juul, Anders ; Kopchick, John ; Luo, Xiaoping ; Neggers, Sebastian ; Netchine, Irène ; Olsson, Daniel S ; Radovick, Sally ; Rosenfeld, Ron G ; Ross, Richard J ; Schilbach, Katharina ; Collett-Solberg, Paulo Ferrez ; Strasburger, Christian J ; Trainer, Peter J ; Wickstrom, Kerstin ; Yuen, Kevin Cj ; Jørgensen, Jens Otto Lunde. / Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. In: Endocrine Connections. 2018 ; Vol. 7, No. 3. pp. R126-R134.

Bibtex

@article{2da98e9a61484f82bb2a5d1fd9d0d40b,
title = "Growth Hormone Research Society perspective on biomarkers of GH action in children and adults",
abstract = "OBJECTIVE: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults, and in patients with acromegaly.PARTICIPANTS: GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry.EVIDENCE: Current literature was reviewed and expert opinion was utilized to establish the state of the art, and identify current gaps and unmet needs.CONSENSUS PROCESS: Following plenary presentations, breakout groups discussed questions framed by the planning committee. The attendees re-convened after each breakout session to share the group reports. A writing team compiled the breakout session reports into a document that was subsequently discussed and revised by participants. This was edited further and circulated for final review after the meeting. Participants from pharmaceutical companies were not part of the writing process.CONCLUSIONS: The clinical endpoint in pediatric GH treatment is adult height with height velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH deficient patients (GHDA) and in patients with acromegaly. The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of co-morbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment, whereas in acromegaly normalization of IGF-I may be related to improvement in mortality. There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly.",
keywords = "Journal Article",
author = "Gudmundur Johannsson and Martin Bidlingmaier and Beverly Biller and Margaret Boguszewski and Casanueva, {Felipe F} and Philippe Chanson and Choong, {Catherine S} and Clayton, {Peter E} and David Clemmons and Mehul Dattani and Jan Frystyk and Ho, {Ken K Y} and Andrew Hoffman and Reiko Horikawa and Anders Juul and John Kopchick and Xiaoping Luo and Sebastian Neggers and Ir{\`e}ne Netchine and Olsson, {Daniel S} and Sally Radovick and Rosenfeld, {Ron G} and Ross, {Richard J} and Katharina Schilbach and Collett-Solberg, {Paulo Ferrez} and Strasburger, {Christian J} and Trainer, {Peter J} and Kerstin Wickstrom and Yuen, {Kevin Cj} and J{\o}rgensen, {Jens Otto Lunde}",
year = "2018",
doi = "10.1530/EC-18-0047",
language = "English",
volume = "7",
pages = "R126--R134",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Growth Hormone Research Society perspective on biomarkers of GH action in children and adults

AU - Johannsson, Gudmundur

AU - Bidlingmaier, Martin

AU - Biller, Beverly

AU - Boguszewski, Margaret

AU - Casanueva, Felipe F

AU - Chanson, Philippe

AU - Choong, Catherine S

AU - Clayton, Peter E

AU - Clemmons, David

AU - Dattani, Mehul

AU - Frystyk, Jan

AU - Ho, Ken K Y

AU - Hoffman, Andrew

AU - Horikawa, Reiko

AU - Juul, Anders

AU - Kopchick, John

AU - Luo, Xiaoping

AU - Neggers, Sebastian

AU - Netchine, Irène

AU - Olsson, Daniel S

AU - Radovick, Sally

AU - Rosenfeld, Ron G

AU - Ross, Richard J

AU - Schilbach, Katharina

AU - Collett-Solberg, Paulo Ferrez

AU - Strasburger, Christian J

AU - Trainer, Peter J

AU - Wickstrom, Kerstin

AU - Yuen, Kevin Cj

AU - Jørgensen, Jens Otto Lunde

PY - 2018

Y1 - 2018

N2 - OBJECTIVE: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults, and in patients with acromegaly.PARTICIPANTS: GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry.EVIDENCE: Current literature was reviewed and expert opinion was utilized to establish the state of the art, and identify current gaps and unmet needs.CONSENSUS PROCESS: Following plenary presentations, breakout groups discussed questions framed by the planning committee. The attendees re-convened after each breakout session to share the group reports. A writing team compiled the breakout session reports into a document that was subsequently discussed and revised by participants. This was edited further and circulated for final review after the meeting. Participants from pharmaceutical companies were not part of the writing process.CONCLUSIONS: The clinical endpoint in pediatric GH treatment is adult height with height velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH deficient patients (GHDA) and in patients with acromegaly. The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of co-morbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment, whereas in acromegaly normalization of IGF-I may be related to improvement in mortality. There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly.

AB - OBJECTIVE: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults, and in patients with acromegaly.PARTICIPANTS: GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry.EVIDENCE: Current literature was reviewed and expert opinion was utilized to establish the state of the art, and identify current gaps and unmet needs.CONSENSUS PROCESS: Following plenary presentations, breakout groups discussed questions framed by the planning committee. The attendees re-convened after each breakout session to share the group reports. A writing team compiled the breakout session reports into a document that was subsequently discussed and revised by participants. This was edited further and circulated for final review after the meeting. Participants from pharmaceutical companies were not part of the writing process.CONCLUSIONS: The clinical endpoint in pediatric GH treatment is adult height with height velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH deficient patients (GHDA) and in patients with acromegaly. The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of co-morbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment, whereas in acromegaly normalization of IGF-I may be related to improvement in mortality. There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly.

KW - Journal Article

U2 - 10.1530/EC-18-0047

DO - 10.1530/EC-18-0047

M3 - Journal article

VL - 7

SP - R126-R134

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 3

ER -

ID: 53311933